Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with ...

Conference Call Begins at 4:30 p.m. Eastern Time TodayEMERYVILLE, Calif.--(BUSINESS WIRE)--$OABI #OABI--OmniAb, Inc. (NASDAQ: ...

Peer reviewed - observational study - humansThe Covid pandemic disrupted children’s ability to self-regulate - according to ...

Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that the Company, both in the USA and in Israel, is not ...

Patient dosing in the FREEDOM2 10 mg/kg cohort is proceeding in Canada and the UK, with data expected in 2H 2026 –– FREEDOM2 trial open in South Korea, Australia, and New Zealand –– Well-funded with ...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March 11th at 4:00 p.m. ET.A ...

U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology -- Received regulatory clearance to initiate FREEDOM2 in South Korea, Australia, and New ...

Pete Pharma, a pharmaceutical innovation and IP development company focused on modernizing dosage forms through advanced 3D ...

LAFAYETTE, LA / ACCESS Newswire / March 4, 2026 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and ...

LAFAYETTE, LA / ACCESS Newswire / March 4, 2026 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and ...

France has launched a fast track clinical trial approval pathway that could reduce authorisation times to as little as 14 ...

Antiverse has raised $9.3M in Series A funding to expand its AI driven antibody discovery platform and has entered a research ...